Short answer
aTYR PHARMA INC (ATYR) filed its Q1 2026 10-Q quarterly report on May 15, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$11M
- +27.5% YoY
- EPS (diluted)
- −$0.11
- +35.3% YoY
Source: XBRL data from the aTYR PHARMA INC (ATYR) Q1 2026 10-Q on SEC EDGAR. USD.
aTYR PHARMA INC Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New Phase 3 efzofitimod study triggered by April 2026 FDA Type C feedback after EFZO-FIT missed its primary endpoint
- Regulatory approval risk: FDA rejected EFZO-FIT results as establishing effectiveness and raised safety concerns over higher unstudied dosing
- Near-term execution risk: planned Phase 3 dosing increases from every four weeks to every three weeks
- Liquidity risk: $68.3 million available as of March 31, 2026, with additional capital required for planned studies
- Financial condition risk: $10.8 million quarterly net loss and $617.0 million accumulated deficit as of March 31, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other aTYR PHARMA INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.